

Sarepta Therapeutics to Host Analyst Q&A Regarding LGMD Programs

CAMBRIDGE, Mass., July 18, 2025 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that senior management will participate in an analyst Q&A session on Friday, July 18, 2025, at 10:30 a.m. Eastern.

The event will be webcast live under the investor relations section of Sarepta's website at: <https://investorrelations.sarepta.com/events-presentations> and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using **this online form**. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on [LinkedIn](#), [X](#), [Instagram](#) and [Facebook](#).

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:

Ian Estepan
617-274-4052
iestepan@sarepta.com

Media Contacts:

Tracy Sorrentino
617-301-8566
tsorrentino@sarepta.com